Coverage from the 2017 meeting of the American Association of Diabetes Educators.
Diabetes advocates are making progress in their quest to get FDA to look at measures other than glycated hemoglobin (A1C) when approving diabetes treatments. But if payers won’t cover them based on new criteria, it won’t matter, said Aaron Kowalski, PhD, chief mission officer for JDRF, formerly the Juvenile Diabetes Research Foundation.
“We need payers to approve stuff based on hypoglycemia reductions, and based on sleep improvements,” Kowalski said toward the end of his remarks Sunday at the meeting of the American Association of Diabetes Educators in Indianapolis, Indiana. “We need payers to be more encompassing.”
Kowalski is among the diabetes advocates and experts from the clinical, research, and pharmaceutical realms who have worked for more than a year to reach consensus on measures for FDA to consider when approving new devices and drugs. A July 21, 2017, meeting convened by the diaTribe Foundation marked a huge step forward, he said. He walked the educators through a process fueled by patient input and reviews of evidence, which led to agreement that besides A1C, regulators should consider, in order:
The movement to look beyond A1C in approving diabetes treatments, especially those for people with type 1 diabetes (T1D), recognizes the enormous effect that hypoglycemia has on health and quality of life, Kowalski said.
“Glycemia comes with tradeoffs,” he said. The more diabetes care can reduce those tradeoffs and bring life closer to what it was before diabetes, the better. To emphasize his point, Kowalski showed the educators slides of predecessors of the continuous glucose monitor (CGM), including a “blue brick” that hung off the waist like a walkie talkie and a “biostator” that confined a person to bed.
More than 20 years ago, the Diabetes Complications and Control Trial showed the relationship between A1C and long-term cardiovascular outcomes, kidney failure, and retinopathy. But “A1C does not capture hypoglycemia,” and it isn’t actionable, Kowalski said.
“High blood sugar is bad, low blood sugar is bad. If you’re swinging between them, it’s bad,” he said. Thus, drugs and devices that help patients avoid highs and lows help reduce the long-term damage of diabetes, let patients sleep, and reduce the fear of an overnight drop in blood sugar that consumes so many patients and families.
As JDRF worked with FDA on standards for the artificial pancreas, Kowalski said, the question came up: what if A1C went up? From the perspective of a person with T1D, the answer is clear: if A1C went up incrementally, say from 6.4% to 6.8%, but the person no longer had repeat episodes of hypoglycemia that landed him in the hospital, that would be a success.
Kowalski reviewed several new devices that offer patients unprecedented levels of control. CGM is becoming more accurate, better than most meters that read glucose levels based on a finger stick blood test. But progress with payers takes time. Kowalski said it took 10 years for JDRF and others to convince CMS to give Medicare patients CGM access, which happened earlier this year.
Despite these developments, “You can’t turn on the news without hearing about healthcare and access issues,” he said. People with diabetes are beset with high deductibles and copayments, as well as the high price of insulin.
“We cannot have people making decisions because they can’t afford insulin,” Kowalski said. “Unacceptable.”
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Gene and Cell Therapies Hold Potential—but How Can Payers Manage Their Costs?
April 18th 2024Presenters at the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting discussed the current promise and future potential of gene and cell therapies, as well as payer management strategies for these costly treatments.
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Commonwealth Fund Report Details Pervasive Racial and Ethnic Disparities in US Health Care, Outcomes
April 18th 2024Using 25 health system performance indicators, the Commonwealth Fund 2024 State Health Disparities Report evaluated racial and ethnic disparities in health care and health outcomes both within and across US states and highlighted the urgent need for equitable health care policies and practices in the US.
Read More
Beyond Insulin: The Impact of Next-Generation Diabetes Technology
April 17th 2024Experts explain how new diabetes technologies like continuous glucose monitors are transforming care beyond intensive insulin therapy, offering personalized insights and improving outcomes for patients of all treatment levels.
Read More